Professor Anne Tybjærg-Hansen received the prestigious Anitschkow Prize from the European Atherosclerosis Society (EAS) in recognition of her research and important work to improve public health.
Professor Tybjærg-Hansen MD works at the Department of Clinical Biochemistry at the Centre of Diagnostic Investigation at Rigshospitalet and she is a professor at the University of Copenhagen. The focus of her research is on changes in hereditary genes and how they affect the development of cardiovascular diseases.
The European Atherosclerosis Society has described the reasons for their choice as follows:
‘Professor Tybjærg-Hansen is a pioneer in using genetics to understand the importance of individual genes for the development of diseases in general. Her approach has been highly original, novel, and continues to be performed at an outstanding level. Her creative and ground-breaking work has influenced, and continues to have significant impact on, Atherosclerosis Societies in Europe in their efforts to understand the mechanisms of atherosclerosis.’
“Receiving this prize is an enormous honour. I always focus on applicability in my research. Working on something that can really help patients is incredibly exciting,” said Anne Tybjærg-Hansen.
Research to provide better treatment
Anne Tybjærg-Hansen has been researching for many years into the significance of genes for the development of common diseases such as cardiovascular diseases, pulmonary diseases, dementia and cancer. The aim of her research is clear: to find the reasons for these diseases and then to develop better treatments.
“Cholesterol is an important factor in everything from heart disease to gallstones. Among other things, we have demonstrated that a particular genetic variant in a group of people means that they have almost half the risk of developing hardening of the arteries. Therefore, this genetic variant is extremely interesting in developing drugs to treat patients with diseases deriving from high levels of cholesterol in the blood such as cardiovascular diseases.
Among the most highly cited in the world
Professor Tybjærg-Hansen is also among the most influential researchers in the world, and a 2017 survey reveals that she is the most highly cited Danish female researcher. The survey was conducted by the American company Clarivate Analytics, who identified the 3,500 international researchers, including 35 Danes, whose work has globally had the most citations in other researchers’ publications.
Professor Tybjærg-Hansen is extremely pleased about this, and she hopes that it will help her research to be quickly translated into new initiatives that can benefit patients.
“It’s hugely important for me that so many other medical researchers find my work relevant and useful. Because this means that my research will be translated into specific interventions and reach patients more quickly,” concluded Anne Tybjærg-Hansen.
See the whole list at clarivate.com
First woman to receive the Anitschkow Prize
Professor Tybjærg-Hansen has received the Anitschkow medal and a prize of EUR 10,000 in recognition of her research. She is the first women and the first Dane to receive the award.
The prize was presented as part of the opening ceremony at the EAS Congress in Portugal on 5 May 2018.
Facts about the EAS
• The European Atherosclerosis Society (EAS) was established in 1964 with the aim of ‘advancing and exchanging knowledge concerning the causes, natural history, treatment and prevention of atherosclerotic disease’.
• The prize is awarded once a year and is named after the Russian pathologist Nikolai Nikolajewitsch Anitschkow (1885-1964). Anitschkow was the first to describe the role of cholesterol in the development of hardening of the arteries.
See the EAS announcement about the Anitschkow Prize winner 2018